Skip to content

Rockwell Medical, Inc.: financial reference

Rockwell Medical net income: -$5.31 million for the year ending 2025-12-31. Total assets: $57.1 million at 2025-12-31.

Context from the filing

Rockwell Medical's 2024 and 2025 EPS uses loss attributable to common stockholders after Series X preferred-stock accretion, not net loss alone. The accretion is $302,000 in 2024 and $153,000 in 2025, producing common losses of $782,000 and $5,467,000. Potential shares are excluded as anti-dilutive. Dollar losses are displayed in thousands; shares and per-share amounts are unscaled. Full reported share counts and USD EPS are preserved. Read the source filing.

For Rockwell Medical in 2015–2017, stock options, unvested restricted share grants and common-share purchase warrants were excluded from diluted loss per share because their effect would have been anti-dilutive during losses. Basic and diluted weighted-average counts therefore match in the filing. These are full share counts and USD per-share amounts from the historical 2017 report; no later split adjustment is applied to this source version. Read the source filing.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assets-2025-12-3157,145,000USD2026-03-26
Total liabilities-2025-12-3120,164,000USD2026-03-26
Stockholders equity-2025-12-3136,981,000USD2026-03-26
Cash and cash equivalents-2025-12-3110,711,000USD2026-03-26
Net income or loss2025-01-012025-12-31-5,314,000USD2026-03-26
Operating cash flow2025-01-012025-12-31-659,000USD2026-03-26
Financing cash flow2025-01-012025-12-314,252,000USD2026-03-26
Investing cash flow2025-01-012025-12-31-8,544,000USD2026-03-26
Retained earnings or deficit-2025-12-31-402,992,000USD2026-03-26
Basic weighted-average shares2025-01-012025-12-3135,974,231shares2026-03-26
Diluted weighted-average shares2025-01-012025-12-3135,974,231shares2026-03-26
Basic earnings per share2025-01-012025-12-31-0.15USD/shares2026-03-26
Diluted earnings per share2025-01-012025-12-31-0.15USD/shares2026-03-26
Income tax expense or benefit2025-01-012025-12-310USD2026-03-26
Net property, plant and equipment-2025-12-314,629,000USD2026-03-26
Share-based compensation expense2025-01-012025-12-311,816,000USD2026-03-26
Operating income or loss2025-01-012025-12-31-4,691,000USD2026-03-26
Current assets-2025-12-3138,163,000USD2026-03-26
Interest expense2023-01-012023-12-312,301,000USD2024-03-21
Current liabilities-2025-12-319,580,000USD2026-03-26
Current accounts payable-2025-12-311,999,000USD2026-03-26
Goodwill carrying amount-2025-12-31921,000USD2026-03-26
Net current accounts receivable-2025-12-318,143,000USD2026-03-26
Net inventory-2025-12-313,424,000USD2026-03-26
Gross profit2025-01-012025-12-3111,695,000USD2026-03-26
Selling, general and administrative expense2018-01-012018-12-3123,082,304USD2019-03-18
Research and development expense2025-01-012025-12-310USD2026-03-26
Common shares outstanding-2025-12-3139,405,302shares2026-03-26
Cash including restricted cash-2025-12-3110,711,000USD2026-03-26
Additional paid-in capital-2025-12-31439,838,000USD2026-03-26
Accumulated other comprehensive income or loss-2025-12-31131,000USD2026-03-26
Operating lease right-of-use asset-2025-12-312,569,000USD2026-03-26
Operating lease liability-2025-12-312,609,000USD2026-03-26
Gross property, plant and equipment-2025-12-3115,350,000USD2026-03-26
Accumulated depreciation on property, plant and equipment-2025-12-3110,721,000USD2026-03-26
Net intangible assets excluding goodwill-2025-12-319,656,000USD2026-03-26
Other noncurrent assets-2025-12-31556,000USD2026-03-26
Other noncurrent liabilities-2024-12-310USD2025-03-20
Accrued current liabilities-2025-12-314,337,000USD2026-03-26
Prepaid expenses and other current assets-2025-12-311,599,000USD2026-03-26
Current contract liabilities-2025-12-310USD2026-03-26
Pre-tax income or loss from continuing operations2025-01-012025-12-31-5,314,000USD2026-03-26
Comprehensive income or loss2025-01-012025-12-31-5,237,000USD2026-03-26
Net income available to common stockholders2025-01-012025-12-31-5,467,000USD2026-03-26
General and administrative expense2025-01-012025-12-3114,032,000USD2026-03-26
Depreciation expense2025-01-012025-12-311,600,000USD2026-03-26
Depreciation, depletion and amortization2025-01-012025-12-312,192,000USD2026-03-26
Nonoperating interest expense2025-01-012025-12-311,124,000USD2026-03-26
Other nonoperating income or expense2025-01-012025-12-31-623,000USD2026-03-26
Interest paid, net2025-01-012025-12-31772,000USD2026-03-26
Proceeds from issuing common stock2025-01-012025-12-317,816,000USD2026-03-26
Operating lease payments2025-01-012025-12-311,872,000USD2026-03-26
Change in accounts receivable2025-01-012025-12-3198,000USD2026-03-26
Change in inventories2025-01-012025-12-31-2,779,000USD2026-03-26
Change in accounts payable2025-01-012025-12-31-870,000USD2026-03-26

Filings

62 Rockwell Medical filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
ROCKWELL MEDICAL, INC. / CIK 0001041024
Captured
SEC response SHA-256
88e8b83e4e95fda016bcc9a5dced4522c975c40fff65ebdbda5ac42b28ba4fb6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001041024.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))